Wulff, Hansen & Co’s AbbVie ABBV Stock Holding History

Wulff, Hansen & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$689K	Buy	2,739 +79	+3%	+$17K	0.53%	52
2026 Q1	$579K	Hold	2,660	–	–	0.59%	51
2025 Q4	$608K	Sell	2,660 -85	-3%	-$19.4K	0.51%	53
2025 Q3	$636K	Hold	2,745	–	–	0.55%	52
2025 Q2	$510K	Hold	2,745	–	–	0.44%	59
2025 Q1	$575K	Hold	2,745	–	–	0.52%	56
2024 Q4	$488K	Sell	2,745 -25	-0.9%	-$4.6K	0.46%	55
2024 Q3	$547K	Hold	2,770	–	–	0.5%	53
2024 Q2	$475K	Sell	2,770 -340	-11%	-$56.3K	0.47%	55
2024 Q1	$566K	Sell	3,110 -45	-1%	-$7.75K	0.57%	51
2023 Q4	$489K	Hold	3,155	–	–	0.54%	50
2023 Q3	$470K	Sell	3,155 -435	-12%	-$63.9K	0.55%	52
2023 Q2	$484K	Sell	3,590 -225	-6%	-$33K	0.54%	52
2023 Q1	$608K	Hold	3,815	–	–	0.69%	47
2022 Q4	$617K	Sell	3,815 -20	-0.5%	-$3.07K	0.75%	43
2022 Q3	$515K	Hold	3,835	–	–	0.64%	49
2022 Q2	$587K	Hold	3,835	–	–	0.67%	48
2022 Q1	$622K	Sell	3,835 -1,520	-28%	-$221K	0.59%	49
2021 Q4	$725K	Buy	+5,355	New	+$633K	0.63%	50

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wulff, Hansen & Co's ABBV Position: Q2 2026 in Review

Wulff, Hansen & Co increased its AbbVie (ABBV) stake by 3% in Q2 2026, buying an estimated $17K and bringing the position to 2,739 shares worth $689K. The position accounts for 0.53% of the portfolio, ranked #52.

Wulff, Hansen & Co first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $725K in Q4 2021. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Wulff, Hansen & Co held 2,739 shares of AbbVie worth $689K as of Q2 2026.
Wulff, Hansen & Co bought 79 AbbVie shares in Q2 2026, an estimated $17K.
AbbVie made up 0.53% of Wulff, Hansen & Co's portfolio in Q2 2026, its #52 holding.
Wulff, Hansen & Co first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
Wulff, Hansen & Co's AbbVie position peaked at $725K in Q4 2021.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wulff, Hansen & Co's 13F filing for Q2 2026, filed 5 Aug 2026.